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Abstract 
Patient-derived xenograft (PDX) tumor models represent a valuable platform for identifying new biomarkers and novel targets, to 
evaluate therapy response and resistance mechanisms. This study aimed at establishment, characterization and therapy testing of 
colorectal carcinoma-derived PDX. We generated 49 PDX and validated identity between patient tumor and corresponding PDX. 
Sensitivity of PDX toward conventional and targeted drugs revealed that 92% of PDX responded toward irinotecan, 45% toward 5- 
FU, 65% toward bevacizumab, and 61% toward cetuximab. Expression of epidermal growth factor receptor (EGFR) ligands correlated 
to the sensitivity toward cetuximab. Proto-oncogene B-RAF, EGFR, Kirsten rat sarcoma virus oncogene homolog gene copy number 
correlated positively with cetuximab and erlotinib sensitivity. The mutational analyses revealed an individual mutational profile of 
PDX and mainly identical profiles of PDX from primary tumor vs corresponding metastasis. Mutation in PIK3CA was a determinant 
of accelerated tumor doubling time. PDX with wildtype Kirsten rat sarcoma virus oncogene homolog, proto-oncogene B-RAF, and 
phosphatidylinositol-4,5-bisphosphate 3-kinaseM catalytic subunit alfa showed higher sensitivity toward cetuximab and erlotinib. To 
study the molecular mechanism of cetuximab resistance, cetuximab resistant PDX models were generated, and changes in HER2, 
HER3, betacellulin, transforming growth factor alfa were observed. Global proteome and phosphoproteome profiling showed a 
reduction in canonical EGFR-mediated signaling via PTPN11 (SHP2) and AKT1S1 (PRAS40) and an increase in anti-apoptotic 
signaling as a consequence of acquired cetuximab resistance. This demonstrates that PDX models provide a multitude of possibilities 
to identify and validate biomarkers, signaling pathways and resistance mechanisms for clinically relevant improvement in cancer 
therapy. 
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Colorectal cancer (CRC) is the third most diagnosed cancer affecting
about 10% of men and 9% of women worldwide. CRC represents the fourth
most common cause of death due to cancer worldwide and the second
in Europe [1] . The inherent complexity of the disease, characterized by
multiple genetic aberrations in interconnected signaling cascades has impact
on therapy outcome and also on drug discovery [2 , 3] . 
CRC is treated by surgery, combined targeted and chemotherapy and
radiation [4] . However, therapeutic success is highly dependent on choosing
the right therapeutic modality for the right patient, who will benefit most
from an appropriate and effective treatment. Regarding chemotherapy of
CRC patients, 5-fluorouracil (5-FU), modulated by leucovorin (LV), was for
decades the only drugs available for CRC and metastatic CRC. Currently,
5-FU is combined with oxaliplatin or irinotecan as first-line treatment.
The introduction of targeted anti-cancer drugs such as bevacizumab and
cetuximab prolonged the survival of CRC patients [5] . 
However, identification of resistance signatures and stratifying responsive
patients is a current challenge in clinical management of CRC. This
demands appropriate and reliable preclinical models that reproduce cancer
pathway dynamics and closely resemble the clinical situation. In this context,
appropriate clinically relevant in vivo models are required, such as patient-
derived xenograft models (PDX). PDX were demonstrated to maintain the
morphological and molecular characteristics of the original heterogeneous
patient tumor and have been identified as a superior model system for
translational research [6] . Several studies have demonstrated that PDX models
can be used for the correct prediction for sensitivity or resistance of the tumor
to better guide therapies for the patient [7–13] . Analysis of clinically validated
biomarkers such as Kirsten rat sarcoma virus oncogene homolog (KRAS)
mutations and resistance to epidermal growth factor receptor (EGFR)
inhibitors in CRC PDX studies led to the same conclusions as clinical trials
and explored resistance signatures for improved therapy in CRC [14 , 15] . 
In this study, we established 49 CRC PDX models, performed thorough
characterization of molecular features such as gene copy number, mutational
status, gene expression as well as proteome profiles. We characterized tumor
responsiveness toward anti-cancer drugs and generated in vivo resistance
models to be used for molecular analysis of key features associated with
cetuximab-induced resistance. Our study strongly supports the power
and value of PDX models as a platform for biomarker identification
and verification and for more pre-clinical testing of individualized cancer
therapies. 
Material and methods 
Patient samples 
Approval of the local ethical committees was given and informed
consent was obtained from all patients prior to sample acquisition and
experimentation. All patient data were used in an anonymized fashion
according to the ethical guidelines. 
Establishment of PDX 
All animal experiments were carried out in accordance to the German
Animal Welfare Act as well as the UKCCCR (United Kingdom Coordinating
Committee on Cancer Research). 
Fresh tumor fragments were transplanted subcutaneously (s.c.) into the
left flank of anaesthetized NOD scid gamma mice. Mice were observed for
maximum 120 d and maintained under sterile and controlled conditions
(22 °C, 50% relative humidity, 12 h light–dark cycle, autoclaved food
and bedding, acidified drinking water). Tumor growth was measured in 2
dimensions with a caliper. Tumor volumes (TV) were determined by theormula: TV = (width ² x length) x 0.5. Tumors were routinely passaged at
V = 1 cm ³. Xenograft material was snap frozen and stored at -80 °C or
rocessed to formalin fixed, paraffin embedded (FFPE) blocks. 
hemosensitivity testing of the PDX 
Groups of 5 mice were randomized to receive either solvent as control or
ne of the respective drugs. Treatment was started at tumor size of approx.
.1 cm ³. For evaluation of therapeutic efficacy, the ratio of the mean TV
f the treated group (T) and the control group (C) was expressed as the
/C-value in percentage. Antitumor activity was also defined based on the 
esponse Evaluation Criteria in Solid Tumors. A relative tumor volume 
RTV, normalized to the TV on the first treatment day) greater than 1.2
as classified as progressive disease (PD), an RTV of 0.7 to 1.2 as stable
isease (SD), an RTV lower than 0.7 as partial response (PR), and a complete
isappearance of the tumor was classified as complete response (CR). 
eneration of cetuximab-resistant PDX sublines 
To generate resistant PDX isogenic models, 2 cetuximab sensitive PDX 
odels were continuously treated with cetuximab for 10 in vivo passages 
weekly treated with increasing doses of cetuximab: 50, 75, 100 mg/kg). 
DX with highest RTV was selected for further passages. The corresponding 
ntreated PDX was passaged in parallel as corresponding sensitive model. 
E-staining of tumor samples 
FFPE blocks were sectioned (5 to 8 μm), deparaffinized. Shock frozen 
issues were cut (4 to 5 μm) and fixed in 96% ethanol for 5 min.
pecimens were stained according to standard hematoxylin eosin protocol 
or histopathological evaluation. 
mmunohistochemistry and immunofluorescence 
For immunohistochemistry frozen sections were fixed with 4% formalin 
t RT, blocked with peroxidase-block, washed in phosphate buffered saline 
PBS) and blocked with a Streptavidin-Biotin block (both from Vector 
aboratories), according to manufacturer’s instructions. Then sections were 
locked with 20% goat serum for 30 min at RT, incubated with the
iotinylated anti-EpCAM antibody (using the Animal Research Kit (Dako), 
:200, 2 h, RT (Enzo Life Sciences), and horse radish peroxidase-labeled 
treptavidin (1:800, 20 min, RT). 
For immunofluorescence FFPE samples were washed in PBS and 
ermeabilized in 0.1% Triton-X, incubated with Cy3-labeled human anti- 
uclei antibody (Merck Millipore, dilution 1:300) 1 h at 37 °C, washed 
n PBS and mounted in glycerol and PBS (1:1) containing 5 μg/mL 4 ′ ,6-
iamidin-2-phenylindole (DAPI) (Roth). Staining was visualized with 3,3 ′ - 
iaminobenzidine substrate (Dako) and counterstained with hematoxylin, 
hen mounted with VectaMount Aqueous Mounting Medium. 
otal DNA extraction from tissues 
Isolation of total DNA from tissues was carried out using the DNeasy 
lood and Tissue kit (QIAGEN) following manufacturer’s instructions. The 
NA was eluted in 200 μL of distilled H 2 O and used for further analysis. 
NA sequencing 
DNA samples from the 49 PDX were analyzed with the Illumina 
ruSeq Amplicon Cancer Panel (Illumina), targeting 212 amplicons from 
8 oncogenes. Paired patient tumor and normal tissue from 3 samples were 






























































































M  analyzed and compared to their respective PDX in order to corroborate the
conservation of the original genetic profile in the xenografts. All reagents
were supplied in the TruSeq Amplicon Cancer Panel Kit (Illumina). MiSeq
sequencing was carried out on Illumina MiSeq Desktop Sequencer. Illumina
Variant Studio 2.1 was used for sample analysis. For correlation analysis,
known SNPs were excluded and only somatic mutations with an allelic
frequency > 5% were considered. 
Total RNA extraction from tissues 
The total RNA from xenograft tissue samples was isolated by using the
RNeasy Mini Kit (QIAGEN) following the manufacturer’s instructions. The
RNA was eluted in RNAse-free 50 μL H 2 O and used for further analyses. 
Gene expression analysis 
The global mRNA expression was compared between sensitive PDX
and its cetuximab resistant counterparts. Transcriptome analysis of 12 CRC
PDX samples was performed using Illumina Beadchips (HumanHT-12,
V4). Sample preparation was done according to the “Whole-Genome Gene
Expression Direct Hybridization Assay GuidePart # 11322355 Rev. A”
from Illumina. For analysis, the Illumina HumanHT-12 array data were
quantile normalized on probe level (47,323 probes) and on gene level
without background correction using Illumina GenomeStudio V2011.1.
cDNA synthesis 
The Reverse-Transcriptase-Kit (Applied Biosystems) was used according
to manufacturer’s instructions to generate a master mix of 1 x RT-
buffer, containing 500 μM dNTP’s, 5.5 mM MgCl 2 , 2.5 μM random
hexamers, 0.4 U/μL RNase inhibitor und 1.25 U/μL MultiScribe-Reverse-
Transkriptase. Then, 200 ng of RNA were diluted in 10 μl RT-buffer and the
RT-PCR reaction was conducted at 25 °C, 10 min; 48 °C, 30 min, and 95
°C, 5 min. 
Gene expression analysis by quantitative real-time PCR 
200 ng of cDNA, TaqMan Fast Master Mix and Gene Expression Assay
kit were combined in a total volume of 20 μL according to manufacturer’s
instructions. The real-time polymerase chain reaction (PCR) was carried out
on a StepOnePlus System and was conducted at 95 °C for 20 s, followed by 40
cycles of 95 °C, 1 s and at 60 °C, 20 s. The amplification plots were evaluated
with the StepOne Software Version 2.3. The threshold cycle (C T ) of the gene
of interest was normalized to the C T of β-actin and the C T -values were
used to compare the expression between samples. 
Enzyme-linked immunosorbent assay 
Protein lysates were generated for EGFR and its ligand analysis.
Tumor tissues were homogenized in 200 μL T-PER Tissue Protein
Extraction Reagent (Life Technologies), supplemented with protease and
phosphatase inhibitors (Sigma-Aldrich). Then, samples were freeze-thawed
and centrifuged 15 min, 4 °C at 13,000 x g. Protein concentration was
measured with a Protein Assay (Bio-Rad), using a bovine serum albumine
(BSA) standard curve and adjusted to 4 μg/μL. DuoSet enzyme-linked
immunosorbent assays were used to measure the concentration of EGFR,
Amphiregulin (AREG), epiregulin (EREG), betacellulin (BTC), EGF,
and transforming growth factor alfa (TGF α) according to manufacturer’s
instructions (USCN Life Science). The concentrations were normalized to
the total protein concentration. 
Protein extraction and digestion 
The tissues were cryo-fractured on dry ice using a Covaris CP02
cr yoPREP Automated Dr y Pulverizer. Proteins were extracted with an 8 Mrea-based extraction buffer and reduced with 5 mM DTT (Thermo Fisher
ierce) for 1 h at 37 °C. Cysteine residues were alkylated by adding IAA
Sigma-Aldrich) to a final concentration of 10 mM, followed by incubation
or 45 min in the dark at 25 °C. Samples were diluted 1:4 with 50 mM Tris-
Cl (pH 8.0). LysC (Wako) was added in an enzyme/substrate ratio of 1:50
ollowed by incubation for 2 h at 25 °C. Trypsin (Promega, enzyme/substrate
atio of 1:50) was added for overnight digestion at 25 °C, then quenched by
cidifying the mixture to a final concentration of 1% FA (Sigma-Aldrich).
he peptide samples were desalted using tC18 SepPak cartridges with a
acuum manifold. 
andem Mass Tag labeling and fractionation 
For multiplexing, 200 μg peptide samples were labeled with 400 μg
andem mass tag (TMT)-10 reagents (Thermo Scientific). The samples 
ere separated by high-pH reversed-phase liquid chromatography using 
gilent 1290 Infinity II LC system into 96 fractions that were combined
n a step-wise manner, into 28 fractions for proteome and 14 fractions for
hosphoproteome analysis. Early-, middle-, and late-eluting peptides were 
ombined by mixing every 28th original fraction for the proteome and every
2th original fraction for the phosphoproteome analysis. A total of 10% by
olume of the material was used for proteome analysis. The remaining 90% of
ach sample was enriched for phosphopeptides by immobilized metal affinity
hromatography using high capacity Fe (III)-NTA cartridges on Agilent 
ravo automated liquid handling platform. 
C-MS/MS analysis 
Tryptic peptides were analyzed on an EASY-nLC 1200 system coupled
o a Q-Exactive HF-X (Thermo Fisher Scientific). The EASY-nLC system
as equipped with a 75 μm x 20 cm column (packed in-house with 1.9 um
18 resin; Reprosil Gold, Dr. Maisch) and operated at a flow rate of 250
L/min applying a 110 min linear gradient from 2 to 90% solvent B (90%
CN, 0.1% FA) in solvent A (3% ACN, 0.1% FA). MS measurements
ere performed on Q Exactive HF-X with the following modifications:
S1 spectra were recorded at a resolution of 60k using a maxIT of 10 ms.
ragment spectra were acquired at 45k resolution using a maxIT of 86 ms for
lobal proteome measurements and a maxIT of 120 ms for phosphoproteome
easurements. 
ata analysis 
For TMT experiments, peptide identification and quantification were 
erformed using MaxQuant (version 1.6.0.1) [16] . Tandem mass spectra
ere searched against human and mouse reference proteome (Uniprot fasta,
ownloaded on 09.01.2017) supplemented with common contaminants. 
or all searches carbamidomethylated cysteine was set as fixed modification
nd oxidation of methionine, N -terminal protein acetylation, and for
mmobilized metal affinity chromatography data also phosphorylation on 
erine, threonine, and tyrosine residues as variable modifications. Trypsin/P 
as specified as the proteolytic enzyme with up to 2 missed cleavage sites
llowed. Results were adjusted to 1% false discovery rate. The reporter-ion
ntensities were corrected for isotopic impurities before using the reporter-
on signals in each MS/MS spectrum for quantitative calculation s [17] . 
tatistical analysis 
All statistical analyses were performed with Graph Pad Prism 5. For the
esponse evaluation in the sensitivity characterization, two-tailed ANOVA- 
est was used. Correlation analysis was performed as Spearman rank-order
orrelation with a two-tailed P value, and Spearman Rho (r S ) were calculated.
ann-Whitney U tests were performed to compare the generated cetuximab





























































































resistant PDX sublines with their sensitive counterparts. A P value of < 0.05
was considered as statistically significant. 
Statistical analysis of proteome and phosphoproteome 
The corrected reporter ion intensities obtained from the mass-
spectrometric measurements were divided by the internal standard mix
reporter ion intensities and log-transformed using the R-statistical software
package [18] . The ratios for the resistant vs control were calculated
and used for the one-sample moderated t test with Proteomics Toolset
for Integrative Data Analysis (Protigy; https://github.com/broadinstitute/
protigy). All identifications were considered significant with adj. P < 0.1 and
reproducibility filter alfa = 0.01 in. Significantly regulated proteins were used
for the Gene Ontology analysis using the DAVID online tool [19] . Heatmaps
were created using pheatmap package in R. 
Results 
Histological characteristics of CRC PDX models 
For establishment of the 49 CRC PDX, 87 surgical tumor samples
(patient characteristics Table 1 ) were used, reflecting an engraftment rate of
56%. The average time to initial engraftment in NOD scid gamma mice was
49.4 ± 19.5 d. Of these 49 PDX, 27 (55%) were derived from colon and 22
(45%) from rectum ( Table 2 ). 
The number of PDX derived from primary tumors was balanced to those
PDX derived from metastases (53% vs 47% respectively). The metastasis-
derived PDX were evenly distributed between metastasis from lung or
liver. Histology of primary CRC patient tumor tissue was compared with
corresponding PDX tissue ( Figure 1 ). 
All PDX showed similar characteristics of adenocarcinomas and
were therefore well comparable with the initial patient tumor sample
( Figure 1 A). This adenocarcinoma histology was maintained through serial
passages ( Figure 1 B). The tumor cells in the PDX expressed the human
epithelial marker EpCAM. Further, they were positive for human nuclei
antibody staining, whereas the surrounding stroma was negative, indicating
murine origin of the stroma in the stably engrafted PDX ( Figure 1 A),
indicating a replacement of human by murine stroma during in vivo passaging
of the PDX. 
Mutational status and genetic stability of CRC PDX models 
Mutation analysis in the PDX revealed frequent mutations in the
prominent oncogenes, such as adenomatous polyposis coli (APC), KRAS,
and P53, as well-known key players in CRC ( Figure 1 C; Suppl. Table 1).
Highest mutational frequency of 67.3% was detected for APC, followed by
55.1% for KRAS and 53.1% for P53 in the 49 CRC PDX. A lower percentage
of PDX possessed mutated NRAS, PTEN, BRAF or PIK3CA (4.1%, 6.1%,
10.2%, or 16.3%, respectively). 
To evaluate whether the PDX retain the genetic profile, mutational
analyses were performed for all models regarding normal-, primary tumor-
and PDX tissues. The mutation analysis of the original patient tumor after
establishment and also over serial passages in 3 representative PDX revealed
mutations in the genes APC, KRAS, PIK3CA, and TP53 of the respective
patient tumor tissues. These were also present in all analyzed passages of the
matched PDX. No mutations were detected in the corresponding normal
tissues. Comparison of primary tumor tissue vs PDX indicated no gains
or losses of mutations throughout the xenografting and passaging process
( Table 3 ) supporting stability of the mutational status within driver oncogenes
and suppressor genes in the PDX. rowth characteristics of the PDX models 
Tumor doubling time (TDT) was determined as one parameter for PDX 
rowth ( Figure 2 ). Mean TDT of the 49 CRC PDX was 9.96 ± 4.73 d, with a
road range between 2.5 and 30.5 d. TDT of 50% of PDX models clustered
n a rather narrow range of 7.1 to 11.7 d. PDX derived from the colon or
ectum were not different in their TDT. Similarly, TDT of PDX derived from
rimary tumors and PDX derived from metastasis did not show differences. 
nalysis of the mutational status of the PDX regarding TDT showed no 
orrelation between mutations in APC, KRAS, TP53, PTEN, BRAF, or 
RAS. Interestingly, mutated PIK3CA ( n = 8 PDX) had a significant impact
 P = 0.019) on TDT (7.1 ± 2.8 d in mutated vs 10.5 ± 4.8 d in wild type
IK3CA; n = 41). 
ensitivity of the PDX models toward drug treatment 
One key parameter of PDX models is responsiveness toward conventional 
nd targeted drugs. 
The sensitivity of PDX toward chemotherapeutics including 5-FU, 
xaliplatin and irinotecan as well as toward targeted drugs bevacizumab, 
etuximab and erlotinib were tested as monotherapy ( Figure 3 A and B
nd Suppl. Tables 2 and 3). The criterion for response was fulfilled, if the
reated to control value (T/C) was < 50%. By this, 44% of the 49 PDX
esponded to 5-FU and 37% to oxaliplatin treatment. Best responses were 
chieved for irinotecan in 92% of the PDX, which can be attributed to
he specific activating metabolism in mice [20] . For the targeted agents, 
est response rates were obtained with cetuximab (61% of PDX) and 
evacizumab (65% of PDX). Erlotinib showed a response in 41% of the 
DX. Interestingly, comparison of PDX models derived from tumor samples 
f the same patient showed almost identical sensitivity profiles ( Figure 3 B,
uppl. Tables 2 and 3). 
Since mutational status of KRAS is recognized as an important biomarker 
or resistance toward EGFR-targeted therapies, the influence of KRAS, 
RAF and PIK3CA was correlated to PDX sensitivity toward cetuximab 
nd erlotinib. Among the sensitive PDX with T/C-value < 25%, only 2/17 
odels (12%) have an activating KRAS mutation. By contrast, 25/32 (78%) 
f resistant PDX carried a KRAS mutation ( Figure 3 C). Of 5 PDX with a
RAF mutation, 3 carrying the V600E mutation (Co5854, Co10302A, and 
o10302B) were resistant to cetuximab. The T/C-values for cetuximab and 
rlotinib were not significantly different between PDX with a mutated or 
 wild type PIK3CA or BRAF. However, more importantly, triple wild-type 
DX for BRAF, KRAS, and PIK3CA were significantly more sensitive toward 
etuximab or erlotinib (significantly lower T/C-values; P = 0.001 or P = 0.01
espectively) than PDX with an activating mutation in 1 or more of these 3
enes ( Figure 3 D). 
nfluence of gene copy numbers on PDX sensitivity toward targeted drugs 
As for gene mutational status, we also analyzed if alterations in gene 
opy numbers (GCN) have an impact on responsiveness of the PDX toward 
argeted drugs and analyzed EGFR, KRAS, NRAS, BRAF, and MET GCN 
lterations ( Figure 4 ). 
This analysis indicated, that 14/49 PDX harbor increased GCN ( > 2) for
GFR ( Figure 4 A, Suppl. Table 4). For KRAS, 3/49 PDX had 5 to 9 copies
f the gene. BRAF amplifications were detected in 9/49 PDX (Co7596 had a
RAF copy number of 23). The correlation analysis revealed better response 
o cetuximab or erlotinib in the PDX with high GCN for EGFR, KRAS,
nd BRAF ( Figure 4 C). This indicates that a potentially higher activity of
GFR/MAPK signaling increases the tumors’ vulnerability toward cetuximab 
r erlotinib therapies. 
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Table 1 
Key clinical data of patients from whom PDX models were established. 
PDX Patient characteristics Tumor sample characteristics 
Gender Age TNM-status Grading Classification Primary site Metastasis 
Type Site 
Co 5676 f 67 T3aN0M0 G2L0V1R0 primary rectum 
Co 5677 m 71 T4bN1M0 G2L0V0R0 primary colon 
Co 5679 f 51 T3N2M1 G3L1V1R0 primary colon 
Co 5682 f 78 T4bN2M0 G2L0V1R0 primary rectum 
Co 5734 m 79 T3bN0M0 G2L0V0R0 primary colon 
Co 5735 m 84 T3N0M1 G2 metastasis rectum met liver 
Co 5736 f 77 T4N0M0 G2L0V0R0 primary rectum 
Co 5771 m 49 T3N1M0 G2LxV0R0 primary rectum 
Co 5776 m 55 yT3N1M1 G3L1V1R0 metastasis rectum syn liver 
Co 5841 m 55 T3N2M1 G3L1V1R0 primary rectum 
Co 5854 f 52 T4N2M0 G3L1V1R0 primary colon 
Co 5896 m 71 T2N0M0 G2L0V0R0 primary rectum 
Co 6044 m 53 T4N2M1 G2L0V1R2 metastasis rectum syn lymph node 
Co 6228 f 60 rpTxNxM1 GxLxVxR0 metastasis colon met liver 
Co 7271 1 f 66 pT2pN1 G3L0V1R0 metastasis colon syn lung 
Co 7475 f 68 pT2pN0 G2 metastasis rectum met lung 
Co 7515 m 53 pT3 pN0M0 L0V0 R0 metastasis rectum met lung 
Co 7523 f 64 pT3pN1cM0 n.a. metastasis colon met lung 
Co 7553A 2 m 77 T3pN1M0 G3 metastasis colon met lung 
Co 7553B 2 m 77 T3pN1M0 G3 metastasis colon met lung 
Co 7567 m 75 pT3pN0M1 R0 metastasis colon syn lung 
Co 7596 f 72 pT3NxcM0C2 n.a. metastasis rectum met lung 
Co 7660 1 f 67 pT2pN1 G3L0V1R0 metastasis colon met lung 
Co 7689 f 58 pT3N2M0 G2c metastasis rectum met lung 
Co 7809 m 67 yrp TxNxM1 R0LxVxG3 metastasis colon syn liver 
Co 7818 m 68 rpTxNxM1 R0LxVxG2 metastasis colon syn lung 
Co 7835 m 75 rpTxNxM1 R0LxVxG2 metastasis colon syn lung 
Co 7888 m 73 yrepTxNxM1 R0LxVxGx metastasis rectum syn liver 
Co 7935 m 65 rpTxNxM1 R0LxVxG2 metastasis rectum syn liver 
Co 9587 f 80 pT3pN0(0/16) G2R0L1V0 primary colon 
Co 9634 f 61 pT3C4pN1C4cM1 L0V0 metastasis colon met liver 
Co 9689A 3 m 53 pT3pN2cM1 L1V1 metastasis rectum met liver 
Co 9689B 3 m 53 pT3pN2cM1 L1V1 metastasis rectum met liver 
Co 9729 m 68 pT3pN1c G3L1V0 primary rectum 
Co 9775 m 67 pT3pN2apM1 G2R0L0V0 primary colon 
Co 9946 m 81 pT4bpN0 G2R0 primary colon 
Co 9978 f 50 pT4apN1bpM1 G2R0L1V1 primary rectum 
Co 9997 4 f 27 pT4apN2b G3R0L1V1 primary rectum 
Co 10,158 m 67 pT4apN0 G2R0L0V0 primary colon 
Co 10,194 m 78 pT3pN0 G2R0L0V0 primary colon 
Co 10300 4 f 27 pT4apN2b G3R0L1V1 metastasis rectum syn liver 
Co10302A 5 m 64 pT4b(m)pN1b G2RXL1V0 primary colon 
Co10302B 5 m 64 pT4b(m)pN1b G2RXL1V0 primary colon 
Co 10,377 m 50 ypT3ypN0 RxL0V1G2 primary colon 
Co 10,383 m 51 pT2pN0pM1 G3R0L0V0 primary rectum 
Co 10,588 m 72 pT3pN0 G2R0 primary colon 
Co 10,764 m 62 yrpT4bpN1apM1 n.a. primary colon 
Co 10,925 m 73 pT3pN2bcM0 R0 primary colon 
Co 11,061 f 81 pT3pN0 G2R0L0V0 primary colon 







c  Impact of EGFR ligand and receptor expression on PDX sensitivity 
toward targeted drugs 
Regarding targeted drug action, we also analyzed expression of EGFR
ligands AREG, EREG, EGF, BTC, and TGF α in association withesponsiveness toward cetuximab or erlotinib. This analysis revealed a 
ignificant ( P < 0.05) correlation for expression of AREG, EREG and
GF α with cetuximab response of the PDX. No such correlation was
etected regarding erlotinib response ( Figure 4 B and C). This reflects the
lose molecular interplay of cetuximab and the respective natural ligands as
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Figure 1. Histological and mutational status of CRC PDX. (A) Staining of the original patient tissue paired to the corresponding PDX tissue. Representative 
patient/PDX pairs were chosen: Co10194 is derived from a primary colon carcinoma sample, Co9978 from a rectum sample, Co7809 was derived from a 
liver metastasis and Co7475 is derived from a lung metastasis. Upper panel, original patient tissue: HE staining; panel 2 to 4, PDX tissue: HE staining; IF 
staining for human nuclei, DAPI = blue; human nuclei = orange (Cy3); IHC staining for EpCAM. (B) Representative HE staining of consecutive passages of 
PDX Co5854 and Co11061 demonstrate characteristic phenotype of human colorectal carcinoma. Scale bar represents 100 μm. (C) Summary of mutational 
















determinant of drug efficacy. By contrast, no significant correlation was found
between sensitivity toward cytostatic drugs and the expression of EGFR and
its ligands. 
Generation and characterization of cetuximab resistant CRC PDX 
We generated isogenic PDX pairs of cetuximab responsive and resistant
models by the continuous treatment of PDX with cetuximab ( Figure 5 ). 
After 10 passages of the PDX with cetuximab, resistance had developed,
reflected by increase in T/C values for the Co7596 model (Co7596_origs Co7596_cetux) from 0.7% up to 74% and for the Co10718 model 
Co10718_orig vs Co10718_cetux) from 23% to 46% ( Figure 5 A). 
For these pairs we determined if emergence of cetuximab resistance 
s associated with alterations in mutational status. The analysis revealed 
o alterations for the mutational status and mutated allele frequency 
 Figure 5 B) of APC, BRAF, KRAS, RET, SMAD4, and TP53 in
o7596_orig vs Co7596_cetux. In Co10718_orig vs Co10718_cetux, 
etuximab resistance was correlated with an increased frequency of mutated 
RAS from 67% to 93% and decreased frequency for SMAD4 from 72% to
5%. This indicates the emergence of rather individual alterations during the 
mergence of cetuximab resistance. 
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Table 2 
Summary of key parameters of the established 49 PDX. 




Generated PDX 49 
PDX derived from colon carcinoma 27 55 
PDX derived from rectum carcinoma 22 45 
PDX derived from primary tumors 26 53 
PDX derived from metastases 23 47 
Liver 11 22 
Lung 11 22 







































2  Since we had observed a significant correlation between GCN of BRAF
and EGFR and response toward targeted drugs, we also analyzed this
correlation regarding cetuximab resistance. However, we did not detect
significant alterations in GCN during emergence of resistance in the 2 models
(Suppl. Table 5). 
Expression alteration of EGFR family members and their ligands during
cetuximab resistance in PDX 
Since targeted therapies aim at EGFR signaling, the expression of the
EGFR receptor family and its ligands was compared in original PDX and
their resistant counterparts. Expression analysis for EGFR, HER2, HER3
and HER4 revealed no significant changes in Co7596_orig vs Co7596_cetux
( Figure 5 C). By contrast, in the Co10718_cetux model, a statistically
significant increase in HER2 and HER3 ( P < 0.05) was detected, pointing
to the diverging response of the CRC tumors toward cetuximab treatment. Table 3 
Patient tumor and matched normal tissue, paired with tissue from diff
sequenced using the TruSeq Amplicon – Cancer Panel. 212 amplicons 
oncogenes are summarized in the table (AA = amino acid, n.a. = not ana
Mutation detected, (AA mutation) 
Patient or PDX, passage APC BRAF 
Co9587, normal tissue - - 
Co9587, patient tumor n.a. n.a. 
Co9587, P0 ins1554;R876 - 
Co9587, P1 ins1554;R876X - 
Co9587, P2 ins1554;R876X - 
Co9587, P3 ins1554;R876X - 
Co9587, P4 ins1554;R876X - 
Co9775 normal tissue - - 
Co9775, patient tumor - - 
Co9775, P0 - - 
Co9775, P1 - - 
Co9775, P3 - - 
Co9775, P4 - - 
Co10925 normal tissue - - 
Co10925, patient tumor E1379X - 
Co10925, P1 E1379X - 
Co10925, P2 E1379X - 
Co10925, P4 E1379X - As expression of EGFR ligands correlated with sensitivity to cetuximab
n the 49 PDX, expression of these molecules was also analyzed in the
etuximab resistant PDX to evaluate potential changes of AREG, EREG,
TC, EGF, or TGF α. In this regard elevated expression only of BTC and
GF α was detected at protein level in the Co7596_cetux, and at mRNA-level
n Co10718_cetux PDX ( Figure 5 D). The concentration of BTC in PDX was
lmost 2-fold in the Co7596_cetux (from 141.95 pg/mg protein to 263.36
g/mg protein) when compared to the original PDX. Also, in Co10718_orig
s Co10718_cetux, a statistically significant difference in C T -values was
etected for BTC, EGF, and TGF α. The expression levels of BTC and TGF α
ere elevated and the level of EGF was lowered. 
olecular analysis of cetuximab resistant CRC PDX 
To obtain a deeper insight into potential alteration mediating resistance
oward cetuximab, differential gene expression of Co7596_orig and 
o7596_cetux, as well as Co10718_orig and Co10718_cetux, was 
erformed ( Figure 6 A). 
The differential gene expression analysis revealed decreased EGFR 
xpression in Co10718_cetux compared to Co10718_orig (Differential 
core = –2.55). HER2 and HER3 were upregulated in Co7596_cetux and
o10718_cetux, respectively. Interestingly, an up-regulation of c-MET was 
een in Co10718_cetux, and BRAF was down-regulated (not significantly) in
o7596_cetux, similarly to its CGN. ( ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001)
roteomics and phosphoproteomic analysis of cetuximab resistant CRC 
DX 
To characterize proteomic and phosphoproteomic changes involved in 
he acquisition of cetuximab resistance in CRC PDX models, we performed
MT labeling-based global proteome and phosphoproteome analysis of 
o10718 and Co7596 resistant models and their sensitive counterparts 
 Figure 6 B, Suppl. Figure 1; Suppl. Table 6). Among the 15,167 proteins and
4,890 phosphosites that were quantified without missing values, we detectederent, sequential passages of the corresponding PDX models was 
in 48 oncogenes were targeted. The results obtained for the main 
lyzed). 
EGFR KRAS MET PIK3CA TP53 
- - - - - 
n.a. G12D n.a. n.a. n.a. 
- G12D - del104 - 
- G12D - del104 - 
- G12D - del104 - 
- G12D - del104 - 
- G12D - del104 - 
- - - - - 
- G12D - - G245S 
- G12D - - G245S 
- G12D - - G245S 
- G12D - - G245S 
- G12D - - G245S 
- - - - - 
- - - - - 
- - - - - 
- - - - - 
- - - - - 
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Figure 2. Tumor doubling times (TDT) of the PXD models. The tumor doubling time was measured once the models were considered as stably established. 

























































w  9095 proteins, 15,237 phosphosites that could be matched to the human
proteome. Of these, 1335 proteins and 1259 phosphosites were significantly
regulated in the Co10718_cetux model (adj. P value < 0.05, one-sample t
test), whereas no significant changes were observed for the Co7596_cetux
model due to sample related variability between replicates (Suppl. Figures 2
and 3). 
We performed pathway enrichment analyses for the significantly up
and down regulated proteins and phosphosites in Co10718 model. Top
20 significantly up and down regulated GO terms and KEGG pathways
are shown in the bar graphs (Suppl. Figure 4). Here, endocytosis, cell-cell
adhesion, tight and adherence junctions related terms were enriched in the
downregulated proteins and phosphosites population of the resistant model. 
We also examined proteomic and phosphoproteomic profiles of proteins
belonging to EGFR and downstream signaling cascades including MAPK,
PI3K/AKT/mTOR and apoptosis pathways (significance cut-off adj. P value
< 0.1, one-sample t test; Figure 6 B). The results on protein level indicated no
significant change on the EGFR itself, while KRAS was slightly upregulated
in the cetuximab resistant model. Notably, among EGFR ligands, AREG
level was increased whereas EREG level was slightly decreased in the
Co10718_cetux model ( Figure 6 B). Also, we found increased levels of RIN1,
a RAS effector protein known to compete with RAF for RAS interaction. 
Deep phosphoproteome analysis showed increased phosphorylation levels
of RIN1 (Ser 351) and its downstream effector ABL. Both proteins
have previously been shown to be involved in EGFR stabilization and
inhibition of macropinocytosis (PMID: 22,976,291). In addition, increased
phosphorylation of DNM1 (dynamin) and RAC1, proteins involved in
endocytosis and re-organization of the actin cytoskeleton was observed. We
detected increased phosphorylation on MAP3K1 (MEKK1) ( Figure 6 B),
known to have unique structural characteristics that mediate its specific
activities including regulation of cell survival and apoptosis [56] . 
Metabolic pathways, cell cycle and mRNA processing, and transport-
related terms were enriched for the upregulated proteins and phosphosites. In
order to further elucidate pathways which are activated or shut down upon
acquired cetuximab resistance, we performed phosphosite-centric PTM-EA (Post Translational Modifications Set Enrichment Analysis) analysis 
sing individual quantified phosphosites ( n = 11,917 phosphosites) of the 
o10718 PDX model and queried against PTMsigDB. PTM-SEA resulted 
n 102 enriched pathway signatures which includes at least 5 matched 
hosphosites. Enrichment scores were calculated for each sample and 
ndividual pathway signatures. To obtain differentially enriched pathway 
cores between cetuximab resistant and sensitive models, we applied two- 
ample moderated t test to the replicates of the Co10718 model. In total, we
etected 23 significantly enriched signatures between resistant and sensitive 
odels ( Figure6 C and D). We observed positive enrichment of EGFR 
nd EGF pathway signatures in the cetuximab sensitive models. Among 
he signatures that showed positive enrichment upon acquired cetuximab 
esistance were proliferative kinase signatures such as CDK1 and CDK6, 
urora kinases and DYRK2. 
iscussion 
This study described the successful establishment of 49 CRC PDX and 
heir thorough characterization. We were able to stably generate PDX with 
etuximab resistance to further explore the molecular features associated with 
mergence of this resistance. We employed these models to explore in detail 
he impact of the EGFR signaling network in the context of chemosensitivity. 
istology, stability, and sensitivity of the PDX 
All 49 engrafted PDX displayed the characteristic adenocarcinoma 
rchitecture with intense uniform membranous and cytoplasmic staining 
or EpCAM [21] . Human nuclei staining confirmed that CRC tumor cells 
econstructed structures of primary tumors by replacing human stroma 
hrough several passages of PDX. In the vast majority of studies, as well as
n our set of PDX, only murine stroma was detected in stably engrafted PDX
22–24] . Regarding growth characteristics, the mean TDT for the 49 PDX 
as 10 d. This indicates that cells growing in a PDX undergo much less
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Figure 3. Chemosensitivity of the PDX models. (A) Three representative chemosensitivity curves of PDX Co9587, Co9689B, and Co10383 are shown. 
Groups of 5 tumor-bearing mice were treated either with vehicle (control group) or specific drug as monotherapy. ( ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001). 
(B) Summary of sensitivity characteristics of the PDX models toward standard of care cytostatic and targeted drugs based on the optimal treated to control 
(optT/C) values, expressed in percent. (C) Sensitivity of PDX models toward cetuximab: the 49 PDX models are arranged according to their optT/C-value for 
cetuximab and are correlated to the KRAS mutational status. The bar below represents the relative tumor volume (RTV) values. The bar colors indicate the 
respective mutational status of KRAS. (D) Comparison of optT/C-values for EGFR-inhibitors cetuximab and erlotinib between PDX with wildtype KRAS, 


















d  divisions compared to xenografts derived from established tumor cell lines,
preventing genetic drift [25] . 
Mutation profiling showed that the key genetic elements driving tumor
growth (e.g., p53, KRAS) in patients were maintained in PDX [26 , 27] .
Frequency of mutations in CRC PDX closely reflects frequency in human
primary tumor samples [22 , 28] . The frequency of 55.1% we describe for
KRAS in the PDX is rather at the upper level of the overall described
frequencies for CRC. However, for CRC in patient tumors and PDX models
frequencies ranging from 35% to 51% were described [15 , 29] . Therefore,
these models are well suited for sensitivity testing [7 , 28 , 30 , 31] . Regarding sensitivity toward drugs our set of PDX reflects the
eterogeneity known for CRC. The T/C-values for the cytostatic drugs 5-
U and oxaliplatin reflect well the clinical response of CRC to the drugs.
rinotecan reached highest response among all cytostatics due to the more
fficient drug metabolism in mice [20] . Lowest response was seen for
xaliplatin. For targeted drugs, T/C-values for erlotinib correlated strongly 
ith those for cetuximab underlining their interference with same signaling 
athway. 
We showed, that GCNs of BRAF, EGFR, and KRAS, correlated to
rug response to EGFR-inhibitors of the PDX. Amplification of EGFR
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Figure 4. Molecular characterization of PDX regarding GCN and AREG/EREG protein expression and chemosensitivity toward targeted drugs. (A) GCN of 
EGFR in the 49 CRC PDX models, determined by a real-time PCR (left panel) and correlation to cetuximab response (right panel). (B) AREG expression at 
protein level (by ELISA) in the PDX models and correlation to cetuximab response (right panel). The protein concentrations have been normalized to the total 
protein content in the sample. Three PDX samples from different passages were measured ( n = 3). (C) Summary of correlation analysis (spearman coefficients 
rs and their corresponding P values) of the GCN of the key molecules of the EGFR network (left table) and the sensitivity of the PDX toward cetuximab and 




















has been associated with sensitivity to cetuximab by several studies,
which is in accordance with our own results [32–35] . Thus, PDX
models can be considered representative of the patient tissue regarding
GCN. 
EGFR pathway and targeted drug response in CRC PDX 
The expression of EGFR and its ligands has been linked to a more
aggressive disease or a poor prognosis in several cancers, including CRC
[35 , 36] . Regarding EGFR ligands, highest and most differential expression
was found for AREG and EREG, indicating their biological relevance in the
PDX. Another analysis of 144 CRC tumors also determined that AREG andREG, are tightly co-expressed in primary tumors as well as in liver metastases
37 , 38] . We showed that this link extends to BTC. Expression of EGFR
igands can be upregulated upon activation of the receptor by the ligand itself
auto-induction), as well as by other members of the EGFR ligand family 
39] . The correlation pattern of ligands and receptors in this study confirms
he redundant EGFR signaling in the PDX. 
Higher expression of AREG and EREG correlated to better tumor growth 
nhibition by cetuximab, which is well documented in CRC patients [40 , 41] .
hese correlations were not observed for erlotinib, underlining different 
echanisms of action of the 2 drugs. TGF α behaved inversely. Since TGF α
s an epithelial-specific autocrine mitogen, but also acts in a paracrine manner 
o modulate the tumor microenvironment, its mitogenic action might protect 
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Figure 5. Analysis of newly generated cetuximab resistant PDX models. (A) The PDX models Co7596 and Co10718 were initially cetuximab sensitive 
(left panels). After continued cetuximab treatment the cetuximab resistant models Co7596-cetux and Co19718_cetux were generated (right panels). (B) 
Comparison of genetic profiles in the 2 PDX pairs by the Illumina TruSeq Amplicon Cancer Panel reflected by mutated allele frequency and specific amino 
acid (AA) mutations. (C) Analysis of relative mRNA expression of EGFR, HER2, HER3, and HER4 in the PDX pairs. (D) Analysis of relative mRNA and 















m  the PDX from tumor growth inhibition. In a study of 62 CRC patients,
AREG and EREG were elevated in sensitive tumors, whereas TGF α behaved
inversely [42] . 
Comparison of the genetic profile between original PDX and cetuximab 
resistant sub-lines 
We generated models of acquired cetuximab resistance to examine relevant
mechanisms of acquired cetuximab-resistance at molecular level. Efforts to
generate preclinical models of cetuximab-resistance from xenograft tumors
have been limited to date [43–45] . The genetic profile and expression of EGFR-related molecules were 
nalyzed in 2 original PDX and their cetuximab-resistant counterparts. 
he mRNA analysis both, by qRT-PCR and also by Illumina, showed a
ownregulation of EGFR expression in Co10718_cetux, as well as an increase
f HER2 and HER3. Such upregulation of the HER2 and HER3 receptors or
heir increased activation as response to EGFR inhibition has been reported in
reclinical models and cancer patients [44 , 46 , 47] . An increased ligand level
e.g., TGF α) was observed in both resistant models, indicating that ligand
roduction can be a mechanism of resistance to EGFR blockade. Redundant
GFR signaling and use of alternative receptors to activate downstream
itogenic cascades are crucial in resistance to cetuximab. Increased expression
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Figure 6. Gene expression and proteome, phosphoproteome analysis of cetuximab sensitive vs resistant PDX. (A) Comparison of the gene expression of EGFR 
receptors and molecules involved in EGFR signal transduction. (B) Heatmaps of significantly changed proteins and phosphosites (One-sample t test, adj. P 
value < 0.1, reproducibility filter = 0.01) within the EGFR, PI3K/AKT/Mtor, and apoptosis pathways (Wiki Pathway annotations) for the Co10718 model. 
P values are calculated with data of 2 replicates for the Co10718_cetux models normalized against Co10718_orig models. The annotation column shows 
2 lanes for 2 replicates of sensitive (Co10718_orig) and cetuximab resistant (Co10718_cetux) models with green and magenta colors, respectively. On the 
heatmap, blue color indicates down-regulation whereas red color corresponds to proteins and phosphosites up-regulated in the cetuximab resistant comparing 
to sensitive pair. (C) Volcano plot of the P values vs the logFC (fold change) of enrichment scores of PTM-SEA (Ref DOI: 10.1074/mcp.TIR118.000943). 
Two-sample t test is performed between resistant and sensitive replicates of the Co10718 model. Proteins crossing the significance lines (|logFC| ≥ 2, P value 












of HER2 and HER3 can open novel treatments that target HER2 and/or
HER3. 
Comparison of the proteomic and phosphoproteomic profile between 
original PDX and cetuximab-resistant sub-lines 
Proteome and phosphoproteome analysis revealed that acquired resistance
to cetuximab in CRC PDX affects multiple pathways downstream of theGFR. Increased phosphosites within the EGFR pathway belong to proteins 
ssociated with the regulation of EGFR trafficking, ubiquitination and 
roteasomal degradation (RIN1, ABL1, CBLB, and SH3KBP1). It was 
emonstrated before that increased EGFR degradation is associated with 
cquired cetuximab resistance in metastatic CRC cells [48] . Additional 
roteins known to play a role in endocytosis and the regulation of cytoskeletal
omponents include dynamin, ABL and the src family kinase-binding protein 
H3KBP1. These phosphorylation events indicate that alterations in EGFR 




















































































and growth factor receptor internalization and trafficking are associated with
resistance to cetuximab and warrant further investigation. 
Deep phosphoproteome profile analysis showed that canonical MAPK
and PI3K/AKT/mTOR pathways have major dephosphorylation events,
such as reduced phosphorylation of pTyr546 of PTPN11 (SHP2), pSer381
of GAB1, pSer183 and pThr246 of AKT1S1 (PRAS40), pSer388 of
RPS6KB1 (p70S6K) kinase, and several phosphosites on its substrate RPS6.
In contrast to downregulated phosphorylation profiles of several MAPK
pathway kinases such as MAP3K4, MAP2K2, or MAP2K5, and other
kinases such as PDK1 and PTK6 in the Co10718_cetux model, we detected
increased phosphorylation on MAP3K1 (MEKK1) ( Figure 6 B). MEKK1 is
known to have unique structural and functional characteristics compared to
other MAPK pathway proteins, that mediate its specific activity including
regulation of cell survival and apoptosis [56] . 
Among the EGFR ligands, AREG level was increased whereas EREG level
was slightly decreased in the Co10718_cetux model. Regulation of AREG
and EREG expression has been reported to be involved in cancer metastasis
and drug resistance in various cancers [49–52] . 
Even though significant downregulation in the phosphorylation
profile of several MAPK pathway proteins was observed, we detected
increased phospho-MAP3K1 in the Co10718_cetux model. Several studies
demonstrated that MAP3K1 promotes cell survival or apoptosis depending
on the cell type, genetic alteration or stimulus [52–54] . In this regard,
decreased Casp3 protein level with increased phosphorylated MAP3K1 and
NF- κB point toward a MAP3K1-mediated cell survival mechanism in this
cetuximab resistance model [55–57] . Thus, tumor profiling on the genome
and proteome level after different treatments can determine possible changes
in the molecular drivers and signaling pathways and elucidate resistance
mechanisms in vivo. 
In summary, a set of CRC PDX was established and extensively
characterized. The genetic and sensitivity profile of the PDX reflects the
heterogeneity of CRC. Correlation analysis of molecules involved in the
EGFR pathway, as well as targeted therapy addressing this pathway, reflected
the dynamics of the EGFR pathway regulation in the PDX models,
confirming them as a tool for preclinical cancer research. 
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